Advertisement

 

 

Key signaling pathways in thyroid cancer.

Key signaling pathways in thyroid cancer.
Author Information (click to view)

Zaballos MA, Santisteban P,


Zaballos MA, Santisteban P, (click to view)

Zaballos MA, Santisteban P,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

The Journal of endocrinology 235(2) R43-R61 doi 10.1530/JOE-17-0266

Abstract

Whole genome sequencing approaches have provided unprecedented insights into the genetic lesions responsible for the onset, progression and dedifferentiation of various types of thyroid carcinomas. Through these efforts, the MAPK and PI3K signaling cascades have emerged as the main activation pathways implicated in thyroid tumorigenesis. The nature of these essential pathways is highly complex, with hundreds of components, multiple points of crosstalk, different subcellular localizations and with the ability to potentially regulate many cellular processes. Small-molecule inhibitors targeting key kinases of these pathways hold great promise as novel therapeutics and several have reached clinical trials. However, while some remarkable responses have been reported, the development of resistance remains a matter of concern and limits the benefit for patients. In this review, we discuss the latest findings on the major components of the MAPK and PI3K pathways, including their mechanisms of activation in physiological and pathological contexts, their genetic alterations with respect to the different types of thyroid carcinomas and the more relevant drugs designed to block their activity.

Submit a Comment

Your email address will not be published. Required fields are marked *

one × 1 =

[ HIDE/SHOW ]